25I Stock Overview
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.021 |
| 52 Week High | UK£0.04 |
| 52 Week Low | UK£0.0002 |
| Beta | 1.47 |
| 1 Month Change | -47.50% |
| 3 Month Change | 16.67% |
| 1 Year Change | 0% |
| 3 Year Change | -76.67% |
| 5 Year Change | -79.41% |
| Change since IPO | -98.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 25I | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.7% | 2.3% | 0.5% |
| 1Y | 0% | -28.6% | 1.3% |
Price Volatility
| 25I volatility | |
|---|---|
| 25I Average Weekly Movement | 1,607.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 25I's share price has been volatile over the past 3 months.
Volatility Over Time: 25I's weekly volatility has decreased from 1859% to 1607% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
ImmuPharma plc Fundamentals Summary
| 25I fundamental statistics | |
|---|---|
| Market cap | €10.40m |
| Earnings (TTM) | -€3.49m |
| Revenue (TTM) | €81.61k |
127.4x
P/S Ratio-3.0x
P/E RatioIs 25I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 25I income statement (TTM) | |
|---|---|
| Revenue | UK£69.96k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£69.96k |
| Other Expenses | UK£3.06m |
| Earnings | -UK£2.99m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0072 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,275.37% |
| Debt/Equity Ratio | 0% |
How did 25I perform over the long term?
See historical performance and comparison